Neuralink将大脑植入试验扩大到全球12个病人,目的是帮助瘫痪的个人控制装置。 Neuralink expands brain implant trials to 12 patients globally, aiming to help paralyzed individuals control devices.

Elon Musk的脑植入公司Neuralink已将其临床试验扩大到全球12名病人, Neuralink, Elon Musk's brain implant company, has expanded its clinical trials to include 12 patients worldwide, up from seven in June. 这些植入装置使用了2 000多天15 000小时,帮助瘫痪的个人用心控制装置。 The implants, used for over 2,000 days and 15,000 hours, help paralyzed individuals control devices with their thoughts. Neuralink计划与英国医院一起在英国开展临床研究,以进一步评估技术的安全性和有效性。 Neuralink plans to launch a clinical study in the UK with British hospitals to further evaluate the technology's safety and effectiveness. 该公司获得了6.5亿美元的资金,并在解决FDA安全问题后开始对人类进行试验. The company secured $650 million in funding and began human trials after addressing FDA safety concerns.